Personalized Corneal Endothelial Disease Treatment and Prevention System

A next-generation system for treating and preventing corneal endothelial diseases, leveraging biomarkers, genomic data, and machine learning to provide personalized and prophylactic treatment options.

The original patent disclosed a composition or method including (T)EW-7197 for treating or preventing corneal endothelial diseases. However, the current treatment options lack personalization and are often reactive rather than proactive. The present inventive concept addresses this limitation by introducing a system that integrates biomarker detection, genomic analysis, and machine learning to provide tailored treatment and prevention strategies.

The inventive concept comprises a biomarker detection module, a (T)EW-7197 dosing module, a genomic analysis module, and a machine learning module. The biomarker detection module identifies specific biomarkers associated with corneal endothelial disease, while the (T)EW-7197 dosing module administers a tailored dose of (T)EW-7197 based on the detected biomarker. The genomic analysis module analyzes a subject's genomic data to identify genetic risk factors, and the machine learning module predicts the likelihood of corneal endothelial disease based on the subject's medical history and genetic profile. The system can also include a corneal endothelial cell stimulation module to stimulate the corneal endothelial cells to increase their density and function.

The inventive concept introduces a paradigm shift in corneal endothelial disease treatment and prevention by integrating biomarkers, genomic data, and machine learning. The use of biomarkers and genomic analysis enables personalized treatment options, while the machine learning module provides a proactive approach to disease prevention. The corneal endothelial cell stimulation module offers an additional innovative aspect, as it stimulates the corneal endothelial cells to increase their density and function.

Alternative embodiments of the inventive concept could include the use of different biomarkers, genomic analysis tools, or machine learning algorithms. The system could also be adapted for use in other ocular diseases or conditions. Additionally, the corneal endothelial cell stimulation module could be replaced with other modules that stimulate the corneal endothelial cells in different ways.

The inventive concept has significant commercial potential in the ophthalmology market, particularly in the areas of corneal endothelial disease treatment and prevention. The system could be marketed to ophthalmologists, optometrists, and hospitals, and could also be used in clinical trials to develop new treatments for corneal endothelial diseases.